Last reviewed · How we verify
Placebo of MCI-186 — Competitive Intelligence Brief
phase 3
Neurology
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo of MCI-186 (Placebo of MCI-186) — Tanabe Pharma Corporation. This is a placebo control arm and contains no active pharmaceutical ingredient.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo of MCI-186 TARGET | Placebo of MCI-186 | Tanabe Pharma Corporation | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo of MCI-186 CI watch — RSS
- Placebo of MCI-186 CI watch — Atom
- Placebo of MCI-186 CI watch — JSON
- Placebo of MCI-186 alone — RSS
Cite this brief
Drug Landscape (2026). Placebo of MCI-186 — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-of-mci-186. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab